DXC-014

N/A

Report date: 2026/04/27 20:02:09

Base Information

Drug NameDXC-014
Drug Alias NameDAC-014DXC-014
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCD276 antigen modulatorsProstate-Specific Membrane Antigen modulators
TargetsCD276 antigenProstate-Specific Membrane Antigen
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsSmall Cell Lung Carcinoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Dac Biotech Company Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Dac Biotech Company Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsSmall Cell Lung Carcinoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A